All In Biotech

Drug Trial Radar · NCT06147648

Early Conversion of Prolonged-release Tacrolimus in Liver Transplantation.

Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Liver Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Nov 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

352

Planned (sponsor's estimate)

Start

Dec 1, 2023

Primary completion

Jul 30, 2025

Study completion Jul 30, 2026

Sponsor

Lead sponsor
Beijing Tsinghua Chang Gung HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tacrolimus is a commonly used immunosuppressant after liver transplantation. A once-daily administration of prolonged-release tacrolimus has been found to improve patient compliance and offer good efficacy and safety. Moreover, there is evidence that this prolonged-release formulation mitigates renal impairment and metabolic syndrome in transplant recipients. Foreign studies have confirmed that it is safe and feasible for liver transplant recipients to switch from immediate-release tacrolimus to prolonged-release tacrolimus during the stable period. At the same time, patients with early conversion are more likely to benefit in terms of graft survival and renal function recovery, and the proportion of drug conversion needs to be further explored. This study aims to assess the efficacy and safety of switching from immediate-release tacrolimus to prolonged-release tacrolimus three months after liver transplantation. Furthermore, it seeks to investigate the impact of this conversion on indicators such as liver function, kidney function, metabolic disease incidence, and infection incidence in patients.

Conditions

  • Liver Transplantation

Interventions

  • Tacrolimus Sustained-release CapsulesDrug

    Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of biopsy-confirmed acute rejection (BPAR) within 3, 6, and 12 months after conversionTime frame: within 3, 6, and 12 months after conversion

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.